

Commuque from the Extraordinary General Meeting of CELLINK AB (publ)

The following is a summary of the decision made by the Extraordinary General Meeting "EGM".

- The EGM resolved on a new issue of shares in accordance with the Board's proposal for the EGM. The decision:
 - The EGM resolved on a new issue of 674,678 Class B shares, resulting in an increase in the share capital by a maximum of SEK 67,467.80.
 - The right to subscribe for the new shares shall be given to Christian Wildmoser, 79,623 shares, Benjamin Steimle, 42,610 shares, Andre Gross, 74,542 shares, Jonas Schöndube, 74,542 shares, Jürg F. Geigy, 110,531 shares, Peter Koltay, 28,248 shares, BioFluidix GmbH, 168,092 shares and HTGF II GmbH & Co.KG, 96,490 shares.
 - The reason for deviating from the shareholders' preferential right is that the issue is made as a so-called non-cash issue, where the subscription proceeds are paid through shares in cytena GmbH. Thus, it has not been used to carry out a rights issue for existing shareholders.
 - For each subscribed share, SEK 297.17308 will be paid (a total of SEK 200,469,140). Payment is to be made through the transfer of 78,461 shares in cytena GmbH according to the Board's report. The subscription price has been calculated as stated above.
 - Subscription shall be made by payment within one week from the day of the decision of the issue.
 - The Board of Directors has the right to extend the subscription period.
 - The new shares entail the right to distribute profits for the first time on the record date, which falls closest after the new share issue has registered.
 - The Board of Directors, or the person that the Board appoints, is authorized to make the minor adjustments required for the decision to be registered with the Swedish Companies Registration Office.

For further information, please contact:

Erik Gatenholm, CEO
Phone: EU +46 73 267 00 00
US +1 (650) 515 5566
Email: eg@cellink.com

Gusten Danielsson, CFO
Phone: +46 70 991 86 04
US +1 (857) 332 2138
Email: gd@cellink.com



CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se.
at: certifiedadviser@penser.se.